The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of tumor size on survival outcome in metastatic renal cell carcinoma patients (mRCC) treated with targeted therapy.
 
Wanling Xie
Consulting or Advisory Role - Bayer
 
Renzo DiNatale
No Relationships to Disclose
 
A. Ari Hakimi
No Relationships to Disclose
 
Frede Donskov
No Relationships to Disclose
 
Camillo Porta
Consulting or Advisory Role - BMS Brazil; Eisai; EUSA Pharma; Ipsen; Janssen; Novartis; Pfizer
Speakers' Bureau - BMS Brazil; Eisai; Ipsen; Novartis; Pfizer
Research Funding - Pfizer
 
M. Neil Reaume
Honoraria - Bayer; Ferring; Merck; Novartis; Roche; Sanofi
Consulting or Advisory Role - Astellas Pharma; Pfizer
 
Naveen S. Basappa
Honoraria - Astellas Pharma; Janssen; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Janssen; Novartis; Pfizer
Travel, Accommodations, Expenses - Astellas Pharma; Janssen; Novartis
 
Aaron Richard Hansen
No Relationships to Disclose
 
Brian I. Rini
Consulting or Advisory Role - Corvus Pharmaceuticals; Merck; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Benoit Beuselinck
No Relationships to Disclose
 
Georg A Bjarnason
No Relationships to Disclose
 
Sandy Srinivas
Consulting or Advisory Role - Genentech/Roche; medivation; Novartis; pfizer
Speakers' Bureau - Genentech
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst)
 
James Brugarolas
Consulting or Advisory Role - Nektar
Research Funding - Genentech/Roche; Peloton Therapeutics
Patents, Royalties, Other Intellectual Property - Pending patent on biomarker of HIF-2 dependency
Other Relationship - Nektar
 
Sun Young Rha
No Relationships to Disclose
 
Lori Wood
Research Funding - Aragon Pharmaceuticals (I); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche Canada (Inst)
 
Aly-Khan A. Lalani
Consulting or Advisory Role - Novartis
Travel, Accommodations, Expenses - Pfizer
 
Dominick Bosse
No Relationships to Disclose
 
Audrey Duquette
No Relationships to Disclose
 
Daniel Yick Chin Heng
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Janssen; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Novartis (Inst); Pfizer (Inst)
 
Toni K. Choueiri
Honoraria - NCCN; UpToDate
Consulting or Advisory Role - alligent; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Eisai; Exelixis; Foundation Medicine; GlaxoSmithKline; Merck; Novartis; Peloton Therapeutics; Pfizer; Prometheus; Roche/Genentech
Research Funding - Agensys (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst)
Travel, Accommodations, Expenses - advisory boards/consultancy